Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0HIGWE
ADC Name
CNTO95-DM1
Synonyms
CNTO95 DM1
   Click to Show/Hide
Organization
Sanofi SA
Drug Status
Investigative
Indication
In total 3 Indication(s)
Colon cancer [ICD11:2B90]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Melanoma [ICD11:2C30]
Investigative
Drug-to-Antibody Ratio
3-4
Structure
Antibody Name
CNTO95
  Antibody Info 
Antigen Name
Integrin alpha-V (ITGAV)
  Antigen Info 
Payload Name
Mertansine DM1
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
  Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
Combination Type
Emtansine
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 28.74
%
A375.S2 cells
Amelanotic melanoma
Tumor Growth Inhibition value (TGI) 
≈ 44.54
%
A375.S2 cells
Amelanotic melanoma
Tumor Growth Inhibition value (TGI) 
≈ 87.23
%
A375.S2 cells
Amelanotic melanoma
Tumor Growth Inhibition value (TGI) 
≈ 95.81
%
A375.S2 cells
Amelanotic melanoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 28.74% (Day 35) Positive ITGAV expression (ITGAV +++/++)
Method Description
On the day of grouping (Day 0), animals were weighed and intravenously injectedwith control ADC at 25 mg/kg. All testand control articles were given in a volume of 1ml/100 gm of body weight. CNTO 364 at 3 mg/kg groups was administered i.v. on a q7dx5 schedule.
In Vivo Model A375.S2 CDX model
In Vitro Model Amelanotic melanoma A375.S2 cells CVCL_0136
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 44.54% (Day 35) Positive ITGAV expression (ITGAV +++/++)
Method Description
On the day of grouping (Day 0), animals were weighed and intravenously injectedwith control ADC at 25 mg/kg. All testand control articles were given in a volume of 1ml/100 gm of body weight. CNTO 364 at 6 mg/kg groups was administered i.v. on a q7dx5 schedule.
In Vivo Model A375.S2 CDX model
In Vitro Model Amelanotic melanoma A375.S2 cells CVCL_0136
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 87.23% (Day 35) Positive ITGAV expression (ITGAV +++/++)
Method Description
On the day of grouping (Day 0), animals were weighed and intravenously injectedwith control ADC at 25 mg/kg. All testand control articles were given in a volume of 1ml/100 gm of body weight. CNTO 364 at 10 mg/kg groups was administered i.v. on a q7dx5 schedule.
In Vivo Model A375.S2 CDX model
In Vitro Model Amelanotic melanoma A375.S2 cells CVCL_0136
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 95.81% (Day 35) Positive ITGAV expression (ITGAV +++/++)
Method Description
On the day of grouping (Day 0), animals were weighed and intravenously injectedwith control ADC at 25 mg/kg. All testand control articles were given in a volume of 1ml/100 gm of body weight. CNTO 364 at 15 mg/kg groups was administered i.v. on a q7dx5 schedule.
In Vivo Model A375.S2 CDX model
In Vitro Model Amelanotic melanoma A375.S2 cells CVCL_0136
References
Ref 1 Anti-integrin immunoconjugates, methods and uses; 2008-01-17.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.